Venetoclax (Venclyxto®)

Assessment Status Rapid review complete
Drug Venetoclax
Brand Venclyxto®
Indication For the treatment of chronic lymphocytic leukaemia (CLL)
Assessment Process
Rapid review commissioned 03/01/2017
Rapid review completed 08/02/2017
Rapid review outcome Full HTA not recommended until further evidence available

Rapid Review

Commenced Completed Outcome
08/05/2018 21/06/2018 Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.

The HSE has approved reimbursement following confidential price negotiations – December 2018.